Equities

China Pharma Holdings Inc

China Pharma Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.2001
  • Today's Change-0.026 / -11.42%
  • Shares traded981.83k
  • 1 Year change-56.97%
  • Beta0.6732
Data delayed at least 15 minutes, as of Nov 09 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

China Pharma Holdings Inc is a company principally engaged in the development, manufacture and marketing of pharmaceutical products. The Company's products are for human use in connection, and with a variety of high-incidence and high-mortality diseases and medical conditions prevalent. The Company manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. In addition, the Company is also engaged in the production of comprehensive healthcare products and protective products.

  • Revenue in USD (TTM)6.25m
  • Net income in USD-4.40m
  • Incorporated1999
  • Employees231.00
  • Location
    China Pharma Holdings Inc2nd Floor, No. 17, Jinpan Road, HaikouHAIKOU 570216ChinaCHN
  • Phone+86 89 866811730
  • Fax+86 89 866819024
  • Websitehttp://www.chinapharmaholdings.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Marizyme Inc364.96k-52.51m2.41m11.00------6.61-0.974-0.9740.004-0.07120.01251.3110.0033,178.18-179.49-59.02-742.64-64.4770.1770.38-14,389.19-9,435.920.038-0.69891.92--176.5999.98-71.22------
Scisparc Ltd0.00-6.96m2.46m3.00--6.92-----1.22-1.510.000.03440.00----0.00-92.51-69.39-152.41-111.07-------527.17----0.9371--113.73---97.61------
Scorpius Holdings Inc9.85m-29.57m2.83m82.00--0.0175--0.288-183.17-200.5653.8951.920.1552--11.08120,061.60-49.90-39.37-59.65-43.1864.27---321.53-1,068.210.3127-43.940.3569--1,789.583.841.96--27.32--
Stemtech Corp5.37m-5.11m2.93m45.00------0.5457-0.0518-0.05180.0529-0.03591.338.3942.31---126.26------77.87---95.16--0.065-2.59----7.94--36.45------
Psyence Biomedical Ltd0.001.52m3.06m------2.02---0.0442-0.04420.00-0.39790.00------1.13--1.20-----------------------2.63------
NovaBay Pharmaceuticals Inc12.02m-15.98m3.39m24.00------0.2821-65.73-65.9121.94-0.45771.212.297.59500,958.30-105.75-61.51-205.52-83.8958.5559.99-87.67-86.470.4302--8.81--2.243.32-2.66---15.46--
China Pharma Holdings Inc6.25m-4.40m3.43m231.00--0.4636--0.5497-0.6254-0.62540.63790.43170.4172.3423.5727,047.32-29.39-29.66-59.89-55.25-25.896.47-70.48-73.090.2449-21.220.3494---13.48-10.6822.50---25.78--
Processa Pharmaceuticals Inc0.00-11.53m3.59m13.00--0.9658-----4.86-4.860.001.140.00----0.00-176.99-84.35-209.96-90.03------------0.0022------59.45---34.05--
Sonoma Pharmaceuticals Inc12.70m-4.56m3.75m172.00--0.5348--0.2952-10.07-10.0720.985.240.8592.914.4773,831.40-30.85-29.36-41.88-40.6538.1738.00-35.91-30.932.47--0.0394---4.05-7.666.13---29.84--
Titan Pharmaceuticals Inc4.00k-5.46m3.81m4.00--0.9548--953.09-6.59-6.590.00494.370.0016--0.17021,000.00-211.58-96.80-368.99-156.65-----136,525.00-406.26---309.960.00---66.97-51.1645.43---65.61--
Shuttle Pharmaceuticals Holdings Inc0.00-7.20m3.88m8.00--3.05-----10.29-10.290.000.38050.00----0.00-123.53---147.27-------------4.320.5076-------112.71------
CYANOTECH CORP23.82m-5.10m4.14m77.00--0.3878--0.1738-0.7549-0.75493.561.530.88952.0512.12309,389.60-19.04-3.46-29.60-4.4624.7234.54-21.41-3.580.3354-6.610.377---0.4616-5.24-53.11---6.42--
Evoke Pharma Inc7.53m-6.53m4.15m4.00--1.56--0.5517-16.23-16.2311.243.630.71280.43074.971,881,428.00-61.83-100.48-136.53-151.1096.97---86.75-480.521.22-19.910.6523--106.51--5.25------
Tian'an Pharmaceutical Co Ltd10.65m3.14m4.16m--0.02320.0051.140.39060.22460.22460.76111.03----------------68.54--29.51--13.3625.660.00--50.51--106.71------
Biofrontera Inc35.24m-13.51m4.75m85.00--0.3997--0.1347-5.29-5.2912.122.141.211.977.27414,623.50-46.20---113.24--47.75---38.33--1.46-3.530.0264--18.82---3,045.47------
Data as of Nov 09 2024. Currency figures normalised to China Pharma Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

0.23%Per cent of shares held by top holders
HolderShares% Held
XTX Markets LLCas of 30 Jun 202428.74k0.17%
G1 Execution Services LLCas of 30 Jun 202410.92k0.06%
First Community Trust, NA (Dubuque, Iowa)as of 30 Sep 202430.000.00%
Two Sigma Securities LLCas of 30 Jun 20240.000.00%
Baader Bank AG (Investment Management)as of 30 Sep 20240.000.00%
UBS Securities LLCas of 30 Jun 20240.000.00%
Citadel Securities LLCas of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.